A Rollover Phase II Study Testing the Biologic Activity and Safety of AGS-003 in Renal Cell Carcinoma Subjects With Prolonged Response or Stable Disease and Ongoing AGS-003 Treatment in Protocol AGS-003-004 or AGS-003-006

Trial Profile

A Rollover Phase II Study Testing the Biologic Activity and Safety of AGS-003 in Renal Cell Carcinoma Subjects With Prolonged Response or Stable Disease and Ongoing AGS-003 Treatment in Protocol AGS-003-004 or AGS-003-006

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Rocapuldencel-T (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Argos Therapeutics Inc
  • Most Recent Events

    • 23 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 23 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 24 May 2016 Monotherapy arm removed, now the trial has only AGS-003 in combination with sunitinib, trial designed changed from parallel assignment to single group assignment
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top